Provided are a heterocyclic compound used as a TAAR1 agonist, a preparation method of the compound, a pharmaceutical composition containing the compound, and a use of the compound as a TAAR1 agonist in preventing and/or treating various CNS-related diseases. Each substituent in the general formula (IA) is the same as defined in the description.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
Provided are a salt form and a crystal form of a PLK1 kinase inhibitor, and a preparation method therefor and the use thereof. Specifically, provided are a salt form and a crystal form of a compound of formula I, a preparation method therefor, and the use thereof in the preparation of a drug for diseases caused by and/or related to PLK1 kinase activity disorders.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The present disclosure relates to a salt form and crystal form of a thienopyrimidine compound, and a preparation method therefor and the use thereof. Specifically, provided are a salt form and crystal form of the compound of formula I, a preparation method therefor, and the use thereof in the preparation of a drug, i.e., a GnRH receptor antagonist.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
4.
NK-3 RECEPTOR ANTAGONIST COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFORE AND USE THEREOF
The present invention relates to an NK-3 receptor antagonist compound or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, and a pharmaceutical composition comprising same. The compound or the pharmaceutically acceptable salt thereof or the stereoisomer thereof, and the pharmaceutical composition have antagonistic activity against the NK-3 receptor, and can be used as an NK-3 receptor antagonist for preventing or treating diseases related to the activity or expression level of the NK-3 receptor.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61P 25/00 - Drugs for disorders of the nervous system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
5.
PREPARATION METHOD OF 2,6-DIOXASPIRO [4,5] DECANE DERIVATIVES AND SALTS THEREOF
The present disclosure provides a preparation method of 2,6-dioxospiral [4,5] decane derivatives and their salts, which has mild reaction conditions, high reaction conversion rate, simple post-processing, and high product purity and is suitable for industrial production.
A CDK2 inhibitor and a preparation method therefor, and a pharmaceutical composition. The present invention further relates to a use of the compound or the pharmaceutical composition in preparation of drugs for preventing or treating related diseases mediated by CDK2, wherein the diseases comprise abnormal cell growth.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Provided are a heterocyclic compound used as a TAAR1 agonist, a preparation method of the compound, a pharmaceutical composition containing the compound, and a use of the compound as a TAAR1 agonist in preventing and/or treating various CNS-related diseases. Each substituent in the general formula (IA) is the same as defined in the description.
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
8.
19-NOR-C3,3-DISUBSTITUTED C21-AZACYCLO-SUBSTITUTED STEROID AND METHOD FOR USING SAME
AAR positive allosteric modulator in prevention and/or treatment of various CNS-related diseases, such as treatment of sleep disorder, mood disorder, insomnia, anxiety, depression, traumatic brain injury (TBI), stress and epilepsy, etc. Substituents in the general formula (I) are defined the same as in the description.
C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61P 25/00 - Drugs for disorders of the nervous system
A series of compounds for regulating activity of a protein kinase, in particular a compound for inhibiting activity of PLK1. Further provided are a pharmaceutical composition containing the compound, and a use of the compound and the pharmaceutical composition thereof in preparing a drug for preventing or treating diseases caused by and/or related to dysregulation of PLK1 kinase activity.
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The present invention relates to a class of gonadotropin-releasing hormone antagonists, which have antagonistic activity to gonadotropin-releasing hormone and can be used for preventing or treating sex hormone-dependent diseases, such as benign prostatic hypertrophy, hysteromyoma, endometriosis, metrofibroma, precocious puberty, amenorrhea, premenstrual syndrome, and dysmenorrhea; or a prodrug, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and a pharmaceutical composition containing same. (I)
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A prodrug of cannabidiol, a preparation method therefor, and a pharmaceutical composition thereof. The present invention further relates to a use of a compound or pharmaceutical composition containing the prodrug in preparation of drugs for treating related diseases of a mammal or person, the diseases comprising epilepsy, spasm, cerebropathy, pain, anxiety and other affective disorders, Parkinson's disease and tremor, multiple sclerosis, cancer, and inflammation, etc.
C07C 47/277 - Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
C07C 219/04 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
C07C 271/44 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
A61K 31/265 - Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
2A2A2A receptor-related diseases, the diseases comprising: non-motor symptoms caused by Parkinson's disease: delusion, illusion, depression, anxiety, cognitive disorder, and sleep disorder; dementia-related mental diseases; major depressive disorder; or negative symptoms of schizophrenia, etc.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Provided are a new impurity compound of rotigotine behenate, and the rotigotine behenate or a preparation thereof containing less than 0.5% by weight of the impurity compound, and an application of the impurity compound as a reference substance in the impurity detection of the rotigotine behenate or the preparation thereof.
The present invention relates to a class of compounds that serve as VMAT2 inhibitors, and relates in particular to a compound represented by formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, and a preparation method therefor, as well as an application thereof in the preparation of a medicament for treating diseases related to VMAT2. (I)
C07D 455/06 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberineAlkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberineAlkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
Goods & Services
Medicines for human purposes; nutraceutical preparations for
therapeutic or medical purposes; pharmaceutical
preparations; drugs for medical purposes; pharmaceutical
preparations acting on the central nervous system;
cardiovascular pharmaceutical preparations; digestives for
pharmaceutical purposes; drugs for the treatment of
intestinal disorders; drugs and preparations for the
treatment of gastrointestinal disease; drugs for the
treatment of cancer; biological preparations for medical
purposes; biological preparations for the treatment of
cancer; stem cells for medical purposes; injectable
pharmaceuticals; pain relief medication; chemical
preparations for medical purposes; contraceptive
preparations; medicinal herbs; pharmaceutical preparation
for the treatment of musculoskeletal disease;
radiopharmaceutical; diagnostic preparations for medical
purposes; biochemical drug; medical reagents for gene
detection; radioactive substances for medical purposes;
gases for medical purposes; disinfectants; cultures of
microorganisms for medical or veterinary use; disinfectants
for chemical toilets; medicines for veterinary purposes;
mothproofing preparations; dressings, medical; teeth filling
material. Retail services for pharmaceutical, veterinary and sanitary
preparations and medical supplies; wholesale services for
pharmaceutical, veterinary and sanitary preparations and
medical supplies; import-export agency services; marketing;
provision of an on-line marketplace for buyers and sellers
of goods and services.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Diagnostic apparatus for medical purposes; medical apparatus
and instruments; analytical apparatus for medical purposes;
radiological apparatus for medical purposes; testing
apparatus for medical purposes; dental apparatus and
instruments; physiotherapy apparatus; apparatus for
artificial respiration; apparatus, devices and articles for
nursing infants; surgical implants comprised of artificial
materials; orthopedic articles; artificial teeth; suture
materials; feeding bottles; contraceptives, non-chemical;
needles for medical purposes; surgical cutlery; droppers for
medical purposes; syringes for injections; mirrors for
surgeons; body rehabilitation apparatus for medical
purposes; apparatus for the regeneration of stem cells for
medical purposes; surgical apparatus and instruments;
apparatus for DNA and RNA testing for medical purposes. Retail services for pharmaceutical, veterinary and sanitary
preparations and medical supplies; wholesale services for
pharmaceutical, veterinary and sanitary preparations and
medical supplies; import-export agency services; marketing;
provision of an on-line marketplace for buyers and sellers
of goods and services. Physical therapy; nursing, medical; pharmacy advice; therapy
services; medical clinic services; hospital services; health
care; medical assistance; medical analysis services for the
diagnosis of cancer; nutrition consultancy services;
chelation therapy services; managed health care services;
chemotherapy services; obstetric services; collection and
preservation of human blood; medical information; medical
assistance consultancy provided by doctors and other health
care professionals; convalescent home services; rest home
services; beauty salon services.
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
Goods & Services
Medicines for human purposes; nutraceutical preparations for
therapeutic or medical purposes; pharmaceutical
preparations; drugs for medical purposes; pharmaceutical
preparations acting on the central nervous system;
cardiovascular pharmaceutical preparations; digestives for
pharmaceutical purposes; drugs for the treatment of
intestinal disorders; drugs and preparations for the
treatment of gastrointestinal disease; drugs for the
treatment of cancer; biological preparations for medical
purposes; biological preparations for the treatment of
cancer; stem cells for medical purposes; injectable
pharmaceuticals; pain relief medication; chemical
preparations for medical purposes; contraceptive
preparations; medicinal herbs; pharmaceutical preparation
for the treatment of musculoskeletal disease; radio
pharmaceutical; diagnostic preparations for medical
purposes; biochemicial drug; medical reagents for gene
detection; radioactive substances for medical purposes;
gases for medical purposes; disinfectants; cultures of
microorganisms for medical or veterinary use; disinfectants
for chemical toilets; medicines for veterinary purposes;
mothproofing preparations; dressings, medical; teeth filling
material. Retail services for pharmaceutical, veterinary and sanitary
preparations and medical supplies; wholesale services for
pharmaceutical, veterinary and sanitary preparations and
medical supplies; import-export agency services; marketing;
provision of an on-line marketplace for buyers and sellers
of goods and services.
Diagnostic apparatus for medical purposes; medical apparatus
and instruments; analytical apparatus for medical purposes;
radiological apparatus for medical purposes; testing
apparatus for medical purposes; dental apparatus and
instruments; physiotherapy apparatus; apparatus for
artificial respiration; apparatus, devices and articles for
nursing infants; surgical implants comprised of artificial
materials; orthopedic articles; artificial teeth; suture
materials; feeding bottles; contraceptives, non-chemical;
needles for medical purposes; surgical cutlery; droppers for
medical purposes; syringes for injections; mirrors for
surgeons; body rehabilitation apparatus for medical
purposes; apparatus for the regeneration of stem cells for
medical purposes; surgical apparatus and instruments;
apparatus for DNA and RNA testing for medical purposes.
20.
COMPOSITION COMPRISING OXADIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF
Disclosed in the present invention are a composition comprising a compound represented by formula (I), a preparation method therefor, and use thereof in the field of diseases relating to IDO1.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Physical therapy; nursing, medical; pharmacy advice; therapy
services; medical clinic services; hospital services; health
care; medical assistance; medical analysis services for the
diagnosis of cancer; nutrition consultancy services;
chelation therapy services; managed health care services;
chemotherapy services; obstetric services; collection and
preservation of human blood; medical information; medical
assistance consultancy provided by doctors and other health
care professionals; convalescent home services; rest home
services; beauty salon services.
Diagnostic apparatus for medical purposes for testing blood sugar levels, cancer cells and DNA; medical apparatus and instruments for monitoring oxymetory, gas analysis, vital signs, blood properties and respiratory events; analytical apparatus for medical purposes for measuring vital signs, blood pressure and heart rate; radiological apparatus for medical purposes; blood testing apparatus; milling apparatus for dental purposes; weight lifting machines for physical therapy; apparatus for artificial respiration; apparatus, devices and articles for nursing infants, namely, baby bottles and baby nursers; surgical implants comprised of artificial materials; orthopedic supports; artificial teeth; suture materials; feeding bottles; contraceptive apparatus, non-chemical; needles for medical purposes; surgical cutlery; droppers for medical purposes; syringes for injections; mirrors for surgeons; body rehabilitation apparatus for medical purposes; apparatus for the regeneration of stem cells for medical purposes; surgical apparatus and instruments; apparatus for DNA and RNA testing for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
Goods & Services
Medicinal preparations for the treatment of infectious diseases and for use in oncology; nutraceutical preparations for use as a dietary supplement; drugs for medical purposes in the nature of antibiotics; pharmaceutical preparations acting on the central nervous system; cardiovascular pharmaceutical preparations; digestives for pharmaceutical purposes; drugs for the treatment of intestinal disorders; drugs and preparations for the treatment of gastrointestinal disease; drugs for the treatment of cancer; biological preparations for the treatment of cancer; stem cells for medical purposes; injectable pharmaceuticals for the treatment of cardiovascular disorders; pain relief medication; chemical preparations for removal and treatment of tumors; contraceptive preparations; medicinal herbs; pharmaceutical preparation for the treatment of musculoskeletal disease; radio pharmaceuticals for the treatment of tumors; diagnostic preparations for medical purposes; biochemical drugs for the treatment of cardiovascular diseases; medical reagents for gene detection; radioactive substances for medical purposes; gases for medical purposes; disinfectants; cultures of microorganisms for medical or veterinary use; disinfectants for chemical toilets; chemical reagents for veterinary purposes; mothproofing preparations; dressings, medical; teeth filling material Retail services, namely, retail store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; import-export agency services; wholesale services, namely, wholesale ordering services for pharmaceutical, veterinary and sanitary preparations and medical supplies; marketing services; provision of an on-line marketplace for buyers and sellers of goods and services
Retail store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; wholesale store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; import-export agency services; marketing services; provision of an on-line marketplace for buyers and sellers of goods and services
25.
DOSAGE REGIMEN OF PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION
Provided herein are simplified dosing regimens for administering paliperidone palmitate to a patient in need of treatment of schizophrenia or schizoaffective disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes; medicines for veterinary
purposes; wadding for medical purposes; gases for medical
purposes; diagnostic preparations for medical purposes;
pharmaceutical preparations; surgical dressings; nutritive
substances for microorganisms; suppositories; disinfectants;
fly destroying preparations; dental lacquer; vermin
destroying preparations.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
35 - Advertising and business services
Goods & Services
(1) Medicines for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia and bipolar disorders; nutraceutical preparations for use as a dietary supplement consisting of vitamins and minerals; pharmaceutical preparations namely antidiabetic pharmaceuticals, anticancer preparations, antidepressants, antitumour drugs, antiviral pharmaceutical preparations; drugs for medical purposes namely antibiotics; pharmaceutical preparations acting on the central nervous system namely central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; cardiovascular pharmaceutical preparations; digestives for pharmaceutical purposes namely pharmaceutical preparations for the treatment of digestive diseases; drugs for the treatment of intestinal disorders; drugs and preparations for the treatment of gastrointestinal disease; drugs for the treatment of cancer; biological preparations for the treatment of cancer namely anti-cancer preparations; stem cells for medical purposes; injectable pharmaceuticals for the treatment of cardiovascular disorders; pain relief medication; chemical preparations for removal and treatment of tumors; contraceptive preparations; medicinal herbs for general health and well being; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; radiopharmaceutical; pharmaceutical and biological preparations namely diagnostic biomarker reagents for medical purposes; biochemical drug for the treatment of cardiovascular disease; medical reagents for gene detection; radioactive substances for the treatment of cancer; gases for medical use; disinfectants for medical apparatus and instruments; media for bacteriological cultures; disinfectants for chemical toilets; anti-infective preparations for veterinary purposes; mothproofing preparations namely moth repellents; dressings, medical; teeth filling material
(2) Diagnostic apparatus for medical purposes for testing blood sugar, cancer cells and DNA; medical apparatus and instruments for monitoring oxymetory, gas analysis, vital signs, blood properties and respiratory events; analytical apparatus for medical purposes for measuring vital signs, blood pressure and heart; radiological equipment for medical purposes; blood testing apparatus for medical purposes; orthodontic instruments for dental purposes; physiotherapy apparatus namely weight lifting machines for physical therapy; apparatus for artificial respiration; nursing appliances namely baby bottles; surgical implants made from artificial materials; orthopedic belts; artificial teeth; suture materials; feeding bottles; contraceptive coils; needles for medical purposes; surgical cutlery; droppers for medical purposes; syringes for injections; mirrors for surgeons; high frequency electromagnetic therapy apparatus; apparatus for the regeneration of stem cells for medical purposes; surgical instruments; apparatus for DNA and RNA testing for medical purposes (1) Retail services for pharmaceutical, veterinary and sanitary preparations and medical supplies; wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; import-export agency services; consultancy and advisory services in the field of business marketing; provision of an on-line marketplace for buyers and sellers of goods and services
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
Goods & Services
(1) Medicines for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia and bipolar disorders; nutraceutical preparations for use as a dietary supplement consisting of vitamins and minerals; pharmaceutical preparations namely antidiabetic pharmaceuticals, anticancer preparations, antidepressants, antitumour drugs, antiviral pharmaceutical preparations; drugs for medical purposes namely antibiotics; pharmaceutical preparations acting on the central nervous system namely central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; cardiovascular pharmaceutical preparations; digestives for pharmaceutical purposes namely pharmaceutical preparations for the treatment of digestive diseases; drugs for the treatment of intestinal disorders; drugs and preparations for the treatment of gastrointestinal disease; drugs for the treatment of cancer; biological preparations for the treatment of cancer namely anti-cancer preparations; stem cells for medical purposes; injectable pharmaceuticals for the treatment of cardiovascular disorders; pain relief medication; chemical preparations for removal and treatment of tumors; contraceptive preparations; medicinal herbs for general health and well being; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; radiopharmaceutical; pharmaceutical and biological preparations for diagnostic purposes; biochemical drug for the treatment of cardiovascular disease; medical reagents for gene detection; radioactive substances for the treatment of cancer; gases for medical use; disinfectants for medical apparatus and instruments; media for bacteriological cultures; disinfectants for chemical toilets; anti-infective preparations for veterinary purposes; mothproofing preparations namely moth repellents; dressings, medical; teeth filling material (1) Retail services for pharmaceutical, veterinary and sanitary preparations and medical supplies; wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; import-export agency services; consultancy and advisory services in the field of business marketing; provision of an on-line marketplace for buyers and sellers of goods and services.
33.
METHOD FOR PREPARING 1,2,5-OXADIAZOLE COMPOUND, AND INTERMEDIATE THEREOF
Disclosed are a pharmaceutical intermediate, i.e., a compound of formula (II) and a preparation method thereof and the use of the compound of formula (II) in the preparation of other compounds.
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Medical preparations for the treatment of psychological and mental disorders, depression, schizophrenia, bipolar disorder, hyperlipidemia, dyslipidemia, Parkinson's disease, Restless Legs Syndrome, cancer, endometriosis, dysfunctional uterine bleeding; medicines for human purposes and drugs for medical purposes namely, sodium aescinate injections for the treatment of cerebral edema and edema caused by trauma or operations and of venous back flow obstruction diseases, sodium glycididazole injections in the nature of radiosensitizer for the radiotherapy of solid tumors such as head and neck tumor, lung cancer, and esophageal cancer, and reduced glutathione injections for the treatment of alcoholic fatty liver, alcoholic liver fibrosis, alcoholic liver cirrhosis, acute alcoholic hepatitis, poisoning by radiotherapy, drugs and chemicals; veterinary pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections, topical infections; first aid kits; wadding for medical purposes; gases for medical use; diagnostic preparations for medical laboratory use; pharmaceutical preparations, chemicopharmaceutical preparations, and chemical preparations for pharmaceutical purposes, namely, sodium aescinate tablets for the treatment of venous edema and soft tissue swelling due to various causes, smectite dispersible tablets and smectite powder sachets for the treatment of acute and chronic bacillary diarrhea of adults and children and for the treatment of pains caused by gullet, stomach and duodenum diseases but not used for spasmolysant, and elcatonin injections for the treatment of bone pains caused by osteoporosis, of hypercalcaemia, and of scleromalacia; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; surgical dressings; radioactive pharmaceutical preparations for in vivo diagnostic or therapeutic use; suppositories for veterinary purposes; castor oil for medical purposes; disinfectants for medical apparatus and instruments; fly destroying preparations; dental lacquer; fly catching adhesives; capsules for pharmaceutical purposes, namely, pantoprazole pellets capsules for the treatment of duodenal ulcer, gastric ulcer and acute pathological changes of gastric mucosa, reflux esophagitis and Zollinger-Ellison Syndrome; antiparasitics; therapeutic medicated bath preparations; dietetic substances consisting of vitamins, minerals, amino acids and trace elements; nutritional supplements for general health and well-being; pesticides for horticultural purposes.
36.
Pharmaceutical compositions of goserelin sustained release microspheres
A composition of goserelin sustained release microspheres is provided. The microspheres comprise goserelin, at least one poly (lactide-co-glycolide) and poloxamer or PEG. The sustained release microspheres have comparatively high bioavailability, which promotes the drug taking its full effect and have entrapment efficiency over 90%.
A compound as an indoleamine-2,3-dioxygenase 1(IDO1) inhibitor, and an application thereof in the field of IDO1-related diseases, and in particular a compound as shown in formula (I) and a pharmaceutically acceptable salts thereof.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to a rotigotine behenate and a manufacturing method and application thereof, and provides a method for manufacturing the rotigotine behenate and an application of the rotigotine behenate in treating a disease related to a dopamine receptor. The structure of the rotigotine behenate is represented by formula I. The fluctuations of plasma concentration of the rotigotine behenate in vivo are small. The rotigotine behenate can maintain an effective plasma concentration for an extended period, has high bioavailability, and can achieve the effect of extended, effective, and stable release.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes; drugs for medical purposes;
capsules for medicines; tonics [medicines]; pharmaceutical
preparations; gelatine for medical purposes; biological
preparations for medical purposes.
An exenatide-containing composition. The composition is in the form of microspheres, the microspheres are prepared by using exenatide acetate and polylactic-co-glycolic acid (PLGA) as raw materials, and the content of acetic acid in the prepared composition is lower than 0.01%. A method for preparing exenatide microspheres comprises: selecting a cleaning fluid of a proper external water phase and a proper amount to clean microspheres, and selecting a proper re-drying temperature to cure the microspheres after the microspheres are freeze-dried. The stability of the microspheres is improved, the drug storage time is prolonged, the particle size is uniform, and a few polymer residues are resulted.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A long acting goserelin sustained release microsphere composition. The microsphere comprises goserelin, at least a lactide/glycolide copolymer, and poloxamer or polyethylene glycol. The sustained release microsphere has a higher bioavailability after being administrated, and makes drug efficacy of the pharmaceutical exert completely. Moreover, the encapsulation efficiency of the prepared microsphere can be more than 90%.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 13/08 - Drugs for disorders of the urinary system of the prostate
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
50.
Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods of preparing the same and use of the same
The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same.
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
C07C 213/10 - SeparationPurificationStabilisationUse of additives
C07C 215/20 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated the carbon skeleton being saturated and containing rings
C07C 215/64 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
C07C 219/28 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
51.
Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methyl-benzoate hydrochloride, methods for preparing the same and use of the same
The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same.
A01N 37/12 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group , wherein Cn means a carbon skeleton not containing a ringThio-analogues thereof
A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
C07C 229/00 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton
52.
PHARMACEUTICAL COMPOSITIONS OF TRIPTORELIN MICROSPHERES
A sustained release triptorelin microsphere is disclosed. The triptorelin microsphere comprises triptorelin or a salt thereof, copolymers lof lactide and glycolide, and glucose or mannitol.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
The present disclosure relates to 5,6,7,8-tetrahydro-6-[N,N-bis[(2-thienyl)ethyl]]amino-1-naphthol, a method for preparing the same, and use of 5,6,7,8-tetrahydro-6-[N,N-bis[(2-thienyl)ethyl]]amino-1-naphthol as a reference compound for determining an impurity in rotigotine or a preparation thereof.
A method for industrially preparing a nitrogen substituted 6-amino-5,6,7,8-tetrahydronaphthol is disclosed. The method comprises reacting a nitrogen substituted amino-5,6,7,8-tetrahydronaphthol compound of formula (II) with a 2-substituted ethyl sulfonate compound of formula (III) under an alkaline condition and in the presence of a sulfite.
C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
C07C 217/12 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a ring other than a six-membered aromatic ring
C07C 217/08 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
C07C 215/64 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, tthe in vivo release behavior of which will not change after long-term storage.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
56.
Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof
The present invention discloses compounds of formula (I), their optical isomers or pharmaceutically acceptable salts thereof, their preparation and uses thereof, wherein the definitions of R1, R2, R3 and R4 are shown in the description. These compounds are optical isomers or racemic mixtures. After these compounds are uptaken, they are metabolically transformated in vivo into 1-[2-dimethylamino-1-(4-hydroxyphenyl)-ethyl]-cyclohexanol that has neuropharmacological activity, by interrupting reuptake of 5-hydroxytryptamine (5-HT) and/or norepinephrine (NA), which is used for treating diseases associated with central nerve system, such as depression, etc.
The disclosure provides a composition comprising rotigotine or a pharmaceutically acceptable salt thereof; at least one poly(lactide-co-glycolide) (PLGA); and at least one fatty acid, wherein the at least one fatty acid is at least 0.5% in weight relative to the total weight of the composition. The composition as disclosed herein has significantly reduced burse release effect. The disclosure also provides a method of treating Parkinson's disease comprising administering an effective amount of the composition as disclosed to a subject in need thereof.
POLYMORPHS OF 4-[2-DIMETHYLAMINO-1-(1-HYDROXYCYCLOHEXYL)ETHYL]PHENYL 4-METHYLBENZOATE HYDROCHLORIDE, METHODS FOR PREPARING THE SAME AND USE OF THE SAME
The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same.
C07C 219/28 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
C07C 213/10 - SeparationPurificationStabilisationUse of additives
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61P 25/00 - Drugs for disorders of the nervous system
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes; medicinal drinks;
pharmaceutical preparations; chemico-pharmaceutical
preparations; chemical preparations for pharmaceutical
purposes; biological preparations for medical purposes;
tonics (medicines); drugs for medical purposes; gelatin for
medical purposes; capsules for pharmaceutical purposes.
60.
Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof
The present invention discloses compounds of formula (I), their optical isomers or pharmaceutically acceptable salts thereof, their preparation and uses thereof, wherein the definitions of R1, R2, R3 and R4 are shown in the description. These compounds are optical isomers or racemic mixtures. After these compounds are uptaken, they are metabolically transformated in vivo into 1-[2-dimethylamino-1-(4-hydroxyphenyl)-ethyl]-cyclohexanol that has neuropharmacological activity, by interrupting reuptake of 5-hydroxytryptamine (5-HT) and/or norepinephrine (NA), which is used for treating diseases associated with central nerve system, such as depression, etc.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances.
62.
COMPOUNDS FOR INHIBITION OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE REUPTAKE OR FOR TREATMENT OF DEPRESSION DISORDERS, THEIR PREPARATION PROCESSES AND USES THEREOF
The present invention discloses compounds of formula (I), their optical isomers or pharmaceutically acceptable salts thereof, their preparation and uses thereof, wherein the definitions of R1, R2, R3 and R4 are shown in the description. These compounds are optical isomers or racemic mixtures. After these compounds are uptaken, they are metabolically transformated in vivo into 1-[2-dimethylamino-1--(4-hydroxyphenyl)-ethyl]-cyclohexanol that has neuropharmacological activity, by interrupting reuptake of 5-hydroxytryptamine (5-HT) and/or norepinephrine (NA) , which is used for treating diseases associated with central nerve system, such as depression, etc.(see formula I)
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61P 25/00 - Drugs for disorders of the nervous system
C07C 215/42 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
C07C 217/60 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07C 219/24 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
63.
COMPOUNDS, PREPARATION PROCESS, AND USES THEREOF USED FOR INTERRUPTING REUPTAKE OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE OR TREATING DISEASES SUCH AS DEPRESSION ET AL.
Compounds of the general formula (I), optical isomers, pharmaceutically acceptable salts, preparation process and uses thereof in which R1, R2, R3 and R4 are as defined in specification are disclosed. Such compounds can be optical isomers or racemic mixtures and can be metabolically transformated into 1-⏧2-dimethylamine-1-(4-hydroxyphenyl)-ethyl]cyclohexanol with new pharmaceutically active in vivo after administration, which can be used for treating diseases associated central nervous system such as depression et al. by interrupting reuptake of 5-hydroxytryptamine (5-HT ) and norepinephrine (NA ) .
C07C 215/42 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
C07C 217/60 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07C 219/24 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61P 25/00 - Drugs for disorders of the nervous system
